Sydney Lupkin
Stories
-
White House proposes to 'march in' on patents for costly drugs
To lower drug prices, the Biden administration is looking to assert its authority to license drug patents that rely on government-funded research to drugmakers that would offer cheaper medicines.
-
Chronic drug shortages stress hospitals and patients
Pharmacists struggle to find key medicines and now have to anticipate drug shortages caused by extreme weather and global instability.
-
World
After hostage deal with Iran, U.S. looks to deter arbitrary arrests abroad
After making a deal to free Americans held in Iran, the U.S. is looking with other countries to find ways to stop countries from making arbitrary arrests.
-
As Ozempic use grows, so do reports of possible mental health side effects
Many people taking Ozempic and related drugs have reported mental health concerns. Those side effects aren't in Ozempic's instructions for use. Are the problems a coincidence or related to the drug?
-
Baby babble isn't just goo goo! And hearing 2 languages is better than one
The science of baby babble is surprisingly complex. And the idea that a baby exposted to two languages will be confused ... let's see what babble researchers have to say about that.
-
National
Fact check: Do lower drug prices make it harder for companies to find new treatments?
The pharmaceutical industry has long said that any attempts to control drug prices would mean disaster for their research and development efforts. But the research doesn't back that up.
-
Here are the first 10 drugs that Medicare will target for price cuts
The government will negotiate new prices for the commonly prescribed drugs, but the cuts won't take effect until 2026. In the meantime, drugmakers are fighting the negotiations with lawsuits.
-
Blockbuster drug Humira finally faces lower-cost rivals
After years of being the world's best-selling drug, Humira faces competition from copycat versions known as biosimilars. One called Yusimry costs a $1,000 or less.
-
National
Copycat drugs could end Humira's reign as the prominent arthritis treatment
The arthritis drug Humira has been a blockbuster seller for more than two decades. Now, some copycats could end Humira's reign.
-
Here's what really happened during the abortion drug's approval 23 years ago
A Texas judge ruled that the Food and Drug Administration wrongly approved mifepristone in 2000 and accused it of doing a rush job. Here's what really went down.